Project Grant R34HL173384
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $771,750 to the Albert Einstein College of Medicine to conduct a cluster randomized controlled trial called "PRAGMATIC-S". The project aims to create an innovative interface between primary care and school-based programs to optimize the delivery of guideline-based asthma care to urban children with persistent or uncontrolled asthma. The award period runs...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $180,174 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia Research Institute. The grant will fund a study to develop a framework for designing the next generation of pediatric acute respiratory distress syndrome (ARDS) clinical trials. Key objectives include: 1) Comparing heterogeneity of treatment effect (HTE) analysis methodologies in a trial of pediatric...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $189,000 Project Grant under CFDA #93.837 Cardiovascular Diseases Research program to the University of Colorado-Denver. The 2-year grant, with a period of performance from September 15, 2025 to August 31, 2027, will support research to investigate the role of outdoor air pollution and environmental allergens in driving treatment response in children with acute asthma...
- This Project Grant award, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to support a mentored implementation science research program focused on improving asthma care and outcomes for children from marginalized communities. The $120,363 award, effective August 18, 2025, will fund Dr. Michelle Eakin's efforts to expand her mentoring program in patient-oriented implementation science. The project will leverage ongoing data collection...
- This Project Grant award of $154,980 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at Seattle Children's Hospital to investigate circadian regulation of epithelial immune responses in asthma. The key activities include: Measuring viral replication and innate immune responses in airway epithelial cell cultures from healthy donors and pediatric asthma patients in relation to cellular circadian time. Comparing circadian gene...
- The federal Project Grant award of $156,899.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to identify distinct clinical phenotypes of pediatric status asthmaticus and evaluate the effects of adjunctive asthma treatments like magnesium and aminophylline across those phenotypes. The primary awardee, Trustees of Indiana University - Indianapolis, will conduct this research over a period from July 2025 to June 2030. The...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is providing $731,130 to the Children's Hospital Medical Center to conduct a study titled "Improving Medication Adherence Using an Adaptive mHealth Intervention in Adolescents with Asthma". The study aims to evaluate the effectiveness of a stepped-care mHealth intervention for improving adherence to daily inhaled corticosteroids in adolescents with asthma. The...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), is funding a research project titled "Emulating Hypothetical Target Trials to Establish the Comparative Effectiveness of Biologics in Asthma." The $834,840 award to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, supports research to generate evidence on the comparative effectiveness of biologic...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $586,021 to The Medical College of Wisconsin, Inc. to establish patient-reported outcome measures that refine neonatal risk stratification and identify barriers to post-discharge specialty care for preterm infants with bronchopulmonary dysplasia (BPD). The goal is to identify hospital-to-home transition strategies that reduce post-prematurity respiratory...
- This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...
This Project Grant award of $427,256 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a randomized, controlled trial to evaluate the use of Bilevel Positive Airway Pressure (BPAP) for managing severe asthma exacerbations in children. The key objectives are to: 1) develop a consensus-based protocol for ED BPAP administration and use of other asthma therapies, 2) determine a primary outcome measure for a future multi-center trial, and 3) assess feasibility to enroll patients, adhere to the BPAP protocol, and complete other study procedures. The award was made to The Trustees of Columbia University in the City of New York, and the project period runs from Sep 15, 2025 to Aug 31, 2027. This grant supports critical research to address the significant healthcare burden of severe pediatric asthma exacerbations requiring intensive care.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $427.3k | 9/13/25 |